| Literature DB >> 24475162 |
Barbara B R Raddatz1, Florian Hansmann1, Ingo Spitzbarth1, Arno Kalkuhl2, Ulrich Deschl2, Wolfgang Baumgärtner1, Reiner Ulrich1.
Abstract
BACKGROUND: Multiple microarray analyses of multiple sclerosis (MS) and its experimental models have been published in the last years.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24475162 PMCID: PMC3903571 DOI: 10.1371/journal.pone.0086643
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of systematic database search.
ArrayExpress and Gene Expression Omnibus (GEO) were searched for microarray gene expression profiling studies with publically available raw data of multiple sclerosis and its experimental animal models with the search terms “Multiple sclerosis”, “EAE” and “Theiler virus”, “Cuprizone” and “Ethidium bromide”. For multiple sclerosis, additional information was gathered from PubMed database using the keywords “multiple sclerosis AND human AND microarray AND (brain OR spinal cord)”. All microarray studies published prior to October 24th 2013, the last time-point of database search, were screened. n = number of records.
Experimental setup of the individual gene expression microarray studies of multiple sclerosis, experimental autoimmune encephalomyelitis, Theiler’s murine encephalomyelitis virus-induced demyelinating disease and transgenic tumor necrosis factor-overexpressing mice included in the current meta-analysis.
| Condition | Reference | ArrayExpressdatabaseaccession number | Platform | Probesets/cDNAs | Genes (UniGeneIds) | Species | Tissue | Experimental design |
|
|
| E-GEOD-38010 | Affymetrix HumanGenome U133Plus 2.0 | 54613 | 29035 | Homo sapiens,male andfemale | brain | Secondary-progressive MS-patients (n = 4); 2 chronic-active and 2 chronic lesions; n = 2 healthy control samples |
|
|
| not applicable | Affymetrix HumanU95A Array | 12627 | 9151 | Homo sapiens,male andfemale | brain | Secondary progressive MS patients (n = 5); controls (n = 12) |
|
|
| not applicable | Custom Array | 3965 | 3771 | Homo sapiens,male andfemale | brain | Secondary-progressive MS-patients (n = 5); 2 acute and 3 chronic lesions; controls (n = 5) |
|
|
| E-MEXP-1025 | Affymetrix RatGenome U34Arrays A,B,C | 26379 | 16010 | Rattus norvegicus,Dark Agouti,female | spinalcord | Experimental study, one factorial design: 1.) control group (n = 3); 2.) EAE acute phase (n = 3); 3.) EAE recovery phase (n = 3); 4.) EAE relapsing phase (n = 4) |
|
|
| E-GEOD-44989 | Affymetrix MouseGenome U74Av2 | 12423 | 8900 | Mus musculusSJL/J,female | spinalcord | Experimental study, one factorial design: 1) control group (n = 3); 2) diseased group (n = 5); pooled samples from two animals each were hybridized per array. |
|
|
| E-MEXP-1717 | Affymetrix MouseGenome 430 2.0 Array | 45101 | 20447 | Mus musculus, SJL/JHanHsd, female | spinalcord | Experimental study, two factorial design: Factor 1: Group (TMEV-infected, Mock-infected); Factor 2: days post infection (14 dpi, 42 dpi, 98 dpi, 196 dpi); independent groups with n = 6, except TMEV-infected 98 dpi, n = 5. |
|
|
| E-MTAB-1 | Custom A-TIGR-5Mouse27 k array, v.1 | 25581 | 13435 | Mus musculus, TNF transgenic lineTg6074, male andfemale | brain | Experimental study, two factorial design: Factor 1: Group (Tg6074 [TNFtg], Wild type [WT]); Factor 2: Time (early: up to 3 weeks of age, late: 3 to 9 weeks of age). TNFtgearly (n = 6), TNFtglate (n = 5), WTearly (n = 2), WTlate (n = 3) |
Differentially expressed genes and enriched biological modules in multiple sclerosis as revealed by re-analysis of publically available microarray data and published gene lists [5], [6], [9].
| Time | Probe sets | Genes | Enriched biological modules | |
|
|
| 3486 | 2650 | Axonogenesis (ES = 6.28), hormone transport (ES = 2.18), negative regulation of actin filament polymerization (ES = 1.52), regulation of cyclase activity (ES = 1.22) |
|
| 2910 | 1933 | Myelination (ES = 2.01), axonogenesis (ES = 1.35) | |
|
|
| 2865 | 2202 | Axonogenesis (ES = 7.58), hormone transport (ES = 1.55), negative regulation of adenylate cyclase activity (ES = 1.45) |
|
| 2616 | 1493 | Myelination (ES = 1.70), neural tube formation (ES = 1.50), positive regulation of transcription from RNA polymerase II promoter (ES = 1.36), axonogenesis (ES = 1.28) | |
|
|
| 94 | 84 | Striated muscle cell development (ES = 1.54), peptide hormone secretion (ES = 1.46), regulation of adenylate cyclase activity (ES = 1.20), axonogenesis (ES = 0.66), regulation of membrane potential (ES = 0.61) |
|
| 35 | 34 | Negative regulation of neuron apoptosis (ES = 1.40), positive regulation of MAP kinase activity (ES = 1.21), regulation of cell morphogenesis involved in differentiation (ES = 0.98), system development (ES = 0.79), cellular ion homeostasis (ES = 0.44) | |
|
|
| 44 | 44 | Cellular carbohydrate catabolic process (ES = 1.02), myelination (ES = 1.94), purine nucleotide biosynthetic process (ES = 1.46), response to steroid hormone stimulus (ES = 1.40), positive regulation of apoptosis (ES = 1.34) |
|
| 43 | 43 | DNA repair (ES = 0.98), protein catabolic process (ES = 0.61), positive regulation of cellular metabolic process (ES = 0.48), regulation of cellular metabolic process (ES = 0.16), macromolecule biosynthetic process (ES = 0.12) | |
|
|
| 38 | 38 | Cellular homeostasis (ES = 5,36), ATP biosynthetic process (ES = 2.20), myelination (ES = 2.04), positive regulation of macromolecule biosynthetic process (ES = 0.87) |
|
| 42 | 42 | Receptor-mediated endocytosis (ES = 0.93), germ cell development (ES = 0.72), modification-dependent protein catabolic process (ES = 0.26) | |
ES = enrichment score.
Differentially expressed genes and enriched biological modules in experimental autoimmune encephalomyelitis as revealed by re-analysis of publically available microarray data [1], [8].
| Time | Probe sets | Genes | Enriched biological modules | |
|
|
| 1213 | 897 | Adaptive immune response (ES = 12.58), positive regulation of lymphocyte activation (ES = 9.00), positive regulation of adaptive immune response (ES = 5.03), cell migration (ES = 4.95), positive regulation of innate immune response (ES = 4.62), response to host (ES = 2.62), positive regulation of type II hypersensitivity (ES = 2.56) |
|
| 1010 | 736 | Regulation of neuron differentiation (ES = 3.85), cell morphogenesis involved in neuron differentiation (ES = 3.43), negative regulation of microtubule depolymerization (ES = 2.73) | |
|
|
| 1080 | 836 | Immunoglobulin mediated immune response (ES = 6.60), positive regulation of adaptive immune response (ES = 4.33), positive regulation of lymphocyte proliferation (ES = 2.86), positive regulation of leukocyte activation (ES = 2.79), regulation of type II hypersensitivity (ES = 2.79), positive regulation of phosphorylation (ES = 2.64), neuron projection morphogenesis (ES = 2.17) |
|
| 1213 | 910 | Acetyl-CoA catabolic process (ES = 4.63), glycolysis (ES = 4.35), ATP biosynthetic process (ES = 1.96), regulation of microtubule depolymerization (ES = 1.96), nucleoside biosynthetic process (ES = 1.48) | |
|
|
| 331 | 244 | Antigen processing and presentation of peptide antigen via MHC class II (ES = 14.29), immunoglobulin mediated immune response (ES = 9.57), regulation of T cell proliferation (ES = 5.92), positive regulation of adaptive immune response (ES = 4.65), positive regulation of type II hypersensitivity (ES = 3.89), humoral immune response (ES = 3.42), induction of apoptosis (ES = 3.22) |
|
| 264 | 188 | Cholesterol biosynthetic process (ES = 6.53) | |
|
|
| 502 | 434 | B cell mediated immunity (ES = 12.97), chemotaxis (ES = 9.38), positive regulation of lymphocyte mediated immunity (ES = 6.53), positive regulation of lymphocyte activation (ES = 6.32), positive regulation of T cell mediated immunity (ES = 5.56), complement activation (ES = 4.74), positive regulation of T cell activation (ES = 4.08), T cell selection (ES = 2.19) |
|
| 41 | 38 | nervous system development (ES = 3.21), cellular homeostasis (ES = 3.20) | |
ES = enrichment score.
Differentially expressed genes and enriched biological modules in Theiler’s murine encephalomyelitis virus-induced demyelinating disease, as revealed by re-analysis of publically available microarray data [3].
| Time | Probe sets | Genes | Enriched biological modules | |
|
|
| 181 | 138 | Positive regulation of immune response (ES = 13.64), immunoglobulin mediated immune response (ES = 8.83), positive regulation of adaptive immune response (ES = 5.97), positive regulation of T cell activation (ES = 5.77), antigen receptor-mediated signaling pathway (ES = 4.82), complement activation, classical pathway (ES = 3.65), positive regulation of T cell mediated cytotoxicity (ES = 3.52), induction of apoptosis (ES = 3.02), positive thymic T cell selection (ES = 2.90) |
|
| 0 | 0 | n.s. | |
|
|
| 614 | 455 | Immunoglobulin mediated immune response (ES = 18.38), complement activation, classical pathway (ES = 7.50), chemotaxis (ES = 6.69), induction of apoptosis (ES = 6.38), positive regulation of type II hypersensitivity (ES = 5.54), negative regulation of mononuclear cell proliferation (ES = 4.09), negative regulation of lymphocyte mediated immunity (ES = 3.64), positive regulation of isotype switching to IgG isotypes (ES = 2.70), positive regulation of interleukin-1 beta secretion (ES = 2.13) |
|
| 0 | 0 | n.s. | |
|
|
| 794 | 581 | Positive regulation of immune response (ES = 31.78), immunoglobulin mediated immune response (ES = 16.87), chemotaxis (ES = 7.91), induction of apoptosis (ES = 7.05), positive regulation of phagocytosis (ES = 6.31), complement activation, classical pathway (ES = 5.85), positive regulation of type II hypersensitivity (ES = 5.02), negative regulation of mononuclear cell proliferation (ES = 4.18), positive regulation of isotype switching to IgG isotypes (ES = 3.98) |
|
| 2 | 2 | n.s. | |
|
|
| 785 | 579 | Immunoglobulin mediated immune response (ES = 19.38), induction of apoptosis (ES = 7.39), positive regulation of phagocytosis (ES = 5.75), complement activation, classical pathway (ES = 5.36), positive regulation of T cell mediated cytotoxicity (ES = 5.18), positive regulation of type II hypersensitivity (ES = 5.17), negative regulation of mononuclear cell proliferation (ES = 3.35) |
|
| 3 | 2 | n.s. | |
ES = Enrichment score; dpi = days post infection; n.s. = no significantly enriched gene ontology terms.
Differentially expressed genes and enriched biological modules in transgenic tumor necrosis factor-overexpressing mice as revealed by re-analysis of publically available microarray data [2].
| Time | Probe sets | Genes | Enriched biological modules | |
|
|
| 12 | 7 | n.s. |
|
| 5 | 4 | n.s. | |
|
|
| 211 | 162 | Complement activation, classical pathway (ES = 1.93), negative regulation of transcription factor activity (ES = 1.10), blood circulation (ES = 1.01), regulation of protein polymerization (ES = 0.91), cellular ion homeostasis (ES = 0.89) |
|
| 2 | 0 | n.s. | |
ES = Enrichment score; n.s. = no significantly enriched gene ontology terms.
Figure 2Venn diagram of the list comparison of differentially expressed genes (DEGs).
Intersections comparing lists of DEGs in multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) and transgenic tumor necrosis factor-overexpressing mice (TNFtg). The numbers in the subsets represent the numbers of the comprised differentially expressed genes, and the grey boxes list the associated enriched biological modules. * = subsets without associated significantly enriched biological modules.
Common differentially expressed orthologous mouse genes in Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), myelin oligodendrocyte glycoprotein (MOG)- and proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE), tumor necrosis factor-overexpressing mice (TNFtg), and multiple sclerosis (MS).
| UniGeneID | Genesymbol | Genetitle | TMEV-IDD | MOG-EAE | PLP-EAE | TNFtg | MS | |||
| FCday 42 | FCday 98 | FCday 196 | FC | FC | FC | FC chronic active | FC chronic | |||
| Mm.101034 | Tgif1 | TG interacting factor 1 | 1.61 | 1.96 | 2.31 | 8.46 | 3.22 | 2.57 | −2.98 | −3.18 |
| Mm.171378 | Ucp2 | Uncoupling protein 2(mitochondrial, proton carrier) | 1.50 | 2.15 | 2.05 | 3.56 | −1.03 | 3.99 | −3.34 | −4.19 |
| Mm.219527 | C1s | Complement component 1, s subcomponent | 2.44 | 2.97 | 3.07 | 2.84 | n.a. | 6.65 | −6.11 | −6.02 |
| Mm.271868 | Laptm5 | Lysosomal-associated protein transmembrane 5 | 2.91 | 3.91 | 3.09 | 6.45 | 3.97 | 4.59 | −15.28 | −9.27 |
| Mm.3317 | Gusb | Glucuronidase, beta | 2.07 | 2.93 | 3.22 | 2.37 | 3.12 | 2.92 | −2.42 | −2.32 |
| Mm.14455 | Tgfbi | Transforming growth factor,beta induced | 2.20 | 2.32 | 2.16 | n.a. | 17.83 | 8.21 | −4.43 | −3.74 |
| Mm.15819 | Cd68 | CD68 antigen | 5.26 | 9.54 | 8.93 | 19.50 | 6.30 | 6.91 | −2.15 | −1.95 |
| Mm.22574 | Csf1r | Colony stimulating factor1 receptor | 2.08 | 2.09 | 1.70 | 4.66 | 3.03 | 2.71 | −3.66 | −3.99 |
| Mm.2277 | Ctsh | Cathepsin H | 3.21 | 4.93 | 4.50 | 2.40 | 6.81 | 5.49 | −3.49 | −3.53 |
| Mm.30010 | Arpc1b | Actin related protein 2/3 complex, subunit 1B | 1.88 | 2.83 | 2.95 | 6.22 | 4.09 | 3.63 | −2.13 | −1.89 |
| Mm.3152 | Lgals3bp | Lectin, galactoside-binding,soluble, 3 binding protein | 8.88 | 10.61 | 7.43 | 6.13 | 6.24 | 23.31 | −11.15 | −10.28 |
| Mm.4219 | Man2b1 | Mannosidase 2, alpha B1 | 1.79 | 2.52 | 2.65 | 2.45 | 3.35 | 2.71 | −2.38 | −2.48 |
FC = Fold change;
significant different gene expression as compared to controls (q <0.05); n.a. = not analyzed (gene not represented on array).
Analysis of commonly affected gene sets (gene ontology terms) in diseased versus control individuals in multiple sclerosis, experimental autoimmune encephalomyelitis, Theiler’s murine encephalomyelitis virus-induced demyelinating disease, and transgenic tumor necrosis factor-overexpressing mice on the pathway level employing Gene Set Enrichment Analysis.
| Gene Set | Genes (N) | Normalizedenrichment score | p-value | q-value |
| Immune system process | 80 | 2.060 | <0.001 | 0.039 |
| Cellular defense response | 13 | 1.892 | <0.001 | 0.041 |
| Homeostatic process | 50 | 1.934 | <0.001 | 0.043 |
| Homeostasis of number of cells | 11 | 1.937 | <0.001 | 0.047 |
| Immune response | 52 | 1.985 | <0.001 | 0.048 |
| Defense response | 48 | 1.857 | <0.001 | 0.058 |
| JAK/STAT cascade | 11 | 1.818 | <0.001 | 0.062 |
| Humoral immune response | 10 | 1.703 | <0.001 | 0.076 |
| Coagulation | 15 | 1.705 | 0.023 | 0.079 |
| Myeloid cell differentiation | 14 | 1.694 | 0.020 | 0.079 |
| Blood coagulation | 15 | 1.705 | 0.023 | 0.083 |
| Regulation of body fluid levels | 16 | 1.709 | 0.023 | 0.084 |
| Response to wounding | 46 | 1.763 | <0.001 | 0.088 |
| Hemostasis | 16 | 1.709 | 0.023 | 0.090 |
| Regulation of signal transduction | 68 | 1.771 | <0.001 | 0.091 |
| Skeletal development | 28 | 1.671 | 0.023 | 0.094 |
| Response to other organism | 15 | 1.721 | <0.001 | 0.095 |
| Glycoprotein metabolic process | 34 | 1.709 | <0.001 | 0.095 |
| Wound healing | 16 | 1.649 | <0.001 | 0.097 |
| Carbohydrate biosynthetic process | 16 | 1.652 | <0.001 | 0.100 |
| Chemical homeostasis | 30 | 1.643 | <0.001 | 0.100 |
N = number of genes in the gene set.
Figure 3Gene set similarity map retrieved by Gene Set Enrichment Analysis (GSEA).
Pathways significantly enriched and positively correlated with disease versus control in multiple sclerosis, experimental autoimmune encephalomyelitis, Theiler’s murine encephalomyelitis virus-induced demyelinating disease and transgenic tumor necrosis factor-overexpressing mice as revealed by cross-study Gene Set Enrichment Analysis. The graph displays a similarity map of GO terms, retrieved by the leading edge analysis GSEA. The intensity of the colour gradient represents a measure for the relative overlap of genes in the respective GO terms, ranging from 100% overlap (dark green) to 0% overlap (white) of the leading edge genes within the GO terms on the x- and y- axis.
Figure 4Venn diagram of differentially expressed genes within each gene signature.
Intersections of differentially expressed genes in experimental autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) and transgenic tumor necrosis factor-overexpressing mice (TNFtg) within the gene signatures for the GO terms “T cell mediated immunity”, “immunoglobulin mediated immune response”, “positive regulation of apoptotic process” and “myelination”. The numbers in the intersections represent the absolute numbers of the comprised differentially expressed genes, and the grey boxes list the associated gene symbols.